All Cancer Patients and Caregivers

We’ve got an opportunity for patients and their caregivers affected by cancer who have undergone chemotherapy or currently in treatment.

Treatment Diaries is seeking opportunities on behalf of our patient community to make your voice heard when it comes to treatment preferences and experiences.  By requesting to be contacted via the link below, not only will your experience have the potential to make a difference  – you’ll be compensated up to $675.00 for your time and willingness to share your experience via a phone interview between now and January 12th, 2017.

Interested?  Know someone who could benefit?  Feel free to share or simply click on this link to learn more and get started!
https://www.surveymonkey.com/r/Cancer_Neulasta


Essential Thrombocythemia (ET)

Background 

QuintilesIMS Global Services, a worldwide consulting firm, is conducting a research study to better understand the experience of ET patients. QuintilesIMS plans to interview patients who have been diagnosed with ET one‐on‐one over the phone. QuintilesIMS is looking for interested people to share what they have gone through since being diagnosed with ET.

Purpose

The overall purpose of the study is to learn which symptoms of ET are the most common, and how these symptoms typically affect the lives of patients like you who live with the disease. This understanding may help improve how the patient’s experience is accounted for in clinical trials that measure the effect of disease treatments. It also may help patients and their families by highlighting the consequences of the disease that most need greater attention, possibly leading to the development of new programs and support services.

Your Involvement

If you qualify, you will be invited to participate in a 75‐minute telephone discussion with one of QuintilesIMS’ healthcare researchers. You will not need to do anything to prepare, other than being ready to describe what your life has been like while living with ET. At no point before, during, or after the interview will you be contacted to purchase anything or be asked to take any medication. You will be one of 20 patients participating in the study and your information will be kept confidential by removing any personal identifiers.

To qualify, patients must have the following criteria:

1. Patient is ≥18 years of age

2. Patient has a current diagnosis of Essential Thrombocythemia (ET) and fulfills one of the following:

· Patient has received hydroxyurea treatment in the past and discontinued it for any reason

OR

· Patient could not receive hydroxyurea because it was contraindicated for the patient

3. Patient has some self‐reported disease related symptom burden

4. Patient is physically and mentally able to participate in an 75 minute interview in English to discuss signs, symptoms, and impacts related to ET

5. Patient is not currently participating in a research study where an investigational agent is being administered

6. Patient has no prior treatment with any oral JAK inhibitor

Compensation

In return for your voluntary participation in the interview, your time and effort will be compensated with a $125 Visa gift card.

Next Steps

To participate, please call Michael Posey from QuintilesIMS, at +1 412‐973‐3162 (Monday‐Friday, 9:00am ‐ 5:00pm EDT), or write to michael.posey@QuintilesIMS.com. Michael will ask for your consent to participate in the study, see if you qualify, then schedule your interview.

Essential Thrombocythemia (ET)

A Double-Blind, Double-Dummy Phase 2 Randomized Study to Evaluate the Efficacy and Safety of Ruxolitinib Versus Anagrelide in Subjects With Essential Thrombocythemia Who Are Resistant to or Intolerant of Hydroxyurea (RESET-272)

The purpose of this study is to evaluate the efficacy and safety of ruxolitinib versus anagrelide in subjects with essential thrombocythemia who are resistant to or intolerant of hydroxyurea.

Talk to your doctor if you are interested in participating in this study.

To find a study center near you, call , then select option 1.

You can also visit clinicaltrials.gov and enter NCT03123588 to learn more.

Multiple Myeloma

Help Us Better Understand Multiple Myeloma Treatment Experiences

Pinpoint Patient Recruiting is seeking individuals with Multiple Myeloma to participate in a market research study about patients’ experiences with treatment decisions for Multiple Myeloma. The feedback will be used to help future patients and their caregivers.

If you are currently being treated for Multiple Myeloma and are receiving your second, third or fourth course of drug therapy (because previous courses of therapy either did not work, stopped working or you experienced a relapse), you may qualify to participate.

If you qualify and complete the online survey, you will receive an honorarium of $75 for your time and participation. All information and responses will remain confidential.

To see if you qualify or to get more information visit: https://www.pinpointpatientrecruiting.com/multiple-myeloma-research-pen

You may also contact Kim Slusher via email at kim@pinpointpatientrecruiting.com.


Myelofibrosis

A Phase 2 Study of the Safety, Tolerability, and Efficacy of INCB050465 in Combination With Ruxolitinib in Subjects With Myelofibrosis

The purpose of this study is to evaluate the safety, tolerability, and efficacy of the combination of INCB050465 and ruxolitinib in subjects with myelofibrosis

Talk to your doctor if you are interested in participating in this study.

To find a study center near you, call , then select option 1.

You can also visit clinicaltrials.gov and enter NCT02718300 to learn more.